Molecular biology of bone remodeling: Implications for new therapeutic targets for osteoporosis
- 11 January 2010
- journal article
- review article
- Published by Elsevier BV in Maturitas
- Vol. 65 (4), 301-307
- https://doi.org/10.1016/j.maturitas.2010.01.002
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone densityJournal of Bone and Mineral Research, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Four-month treatment with GLP-2 significantly increases hip BMDBone, 2009
- Local delivery of rolipram, a phosphodiesterase-4-specific inhibitor, augments bone morphogenetic protein-induced bone formationJournal of Bone and Mineral Metabolism, 2009
- Role of protein-tyrosine phosphatases in regulation of osteoclastic activityCellular and Molecular Life Sciences, 2009
- Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblastsBone, 2008
- Drug-induced morphea: Report of a case induced by balicatib and review of the literatureJournal of the American Academy of Dermatology, 2008
- Chloride Channel ClCN7 Mutations Are Responsible for Severe Recessive, Dominant, and Intermediate OsteopetrosisJournal of Bone and Mineral Research, 2003
- Osteoclast differentiation and activationNature, 2003
- Total bone calcium in normal women: Effect of age and menopause statusJournal of Bone and Mineral Research, 1987